ELI LILLY AND COMPANY |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 726.1 EUR | -0.11% |
|
+4.33% | +37.38% |
| 07:42am | Obesity drugmaker Novo Nordisk raises outlook, Q1 profit beats forecast | RE |
| 07:32am | Obesity drugmaker Novo Nordisk's Q1 profit beats forecast | RE |
| Sales 2024 * | 43.03B 40.2B 3,439B | Sales 2025 * | 51.95B 48.53B 4,151B | Capitalization | 699B 653B 55,886B |
|---|---|---|---|---|---|
| Net income 2024 * | 12.03B 11.24B 961B | Net income 2025 * | 16.09B 15.03B 1,286B | EV / Sales 2024 * | 16.7 x |
| Net Debt 2024 * | 20.93B 19.55B 1,672B | Net Debt 2025 * | 13.85B 12.94B 1,107B | EV / Sales 2025 * | 13.7 x |
| P/E ratio 2024 * |
57.4
x | P/E ratio 2025 * |
42.8
x | Employees | 43,000 |
| Yield 2024 * |
0.67% | Yield 2025 * |
0.77% | Free-Float | 99.83% |
More Fundamentals
* Assessed data
More news
Latest transcript on Eli Lilly and Company
More recommendations
More press releases
More news
| 1 day | -0.17% | ||
| 1 week | +4.33% | ||
| Current month | -0.17% | ||
| 1 month | +1.72% | ||
| 3 months | +21.56% | ||
| 6 months | +36.21% | ||
| Current year | +37.38% |
1 week
670.00
742.80
1 month
670.00742.80
Current year
529.00742.80
1 year
364.60742.80
3 years
152.05742.80
5 years
94.66742.80
10 years
41.83742.80
| Managers | Title | Age | Since |
|---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 31/12/95 |
Anat Ashkenazi
DFI | Director of Finance/CFO | 51 | 31/12/00 |
Ruth Gimeno
PSD | President | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 24/01/21 | |
Ralph Alvarez
BRD | Director/Board Member | 68 | 31/03/09 |
Jon Fyrwald
BRD | Director/Board Member | 63 | 31/12/04 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/05/24 | 723.3 | -0.50% | 116 |
| 30/04/24 | 726.9 | +5.78% | 717 |
| 29/04/24 | 687.2 | +0.12% | 780 |
| 26/04/24 | 686.4 | +1.39% | 542 |
| 25/04/24 | 677 | -1.02% | 556 |
Delayed Quote Deutsche Boerse AG, May 02, 2024 at 11:35 am
More quotes
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
06/05/2024
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
776.8
USD
Average target price
845.3
USD
Spread / Average Target
+8.83%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +26.16% | 571B | |
| -3.55% | 364B | |
| +18.16% | 326B | |
| +4.36% | 286B | |
| +14.92% | 236B | |
| +4.83% | 198B | |
| -10.27% | 194B | |
| -3.69% | 149B | |
| -5.59% | 154B |
- Stock Market
- Equities
- LLY Stock
- LLY Stock
